Cue Biopharma achieves preclinical milestone with Boehringer Ingelheim; $7.5M payment due May 2026

Cue Biopharma, Inc.

Boehringer Ingelheim approved selection of first compound for lead optimization under April 2025 collaboration.
Milestone triggers $7.5M payment to Cue Biopharma, expected in May 2026.
Collaboration targets differentiated B cell depletion molecules including CUE-501.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.